A narrative review of genetic factors affecting fluoropyrimidine toxicity
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Objective: Our objective is to document progress in developing personalized therapy with fluoropyrimidine drugs (FPs) to improve outcomes for cancer patients and to identify areas requiring further investigation. Background: FPs including 5-fluorouracil (5-FU), are among the most widely used drugs for treating colorectal cancer (CRC) and other gastrointestinal (GI) malignancies. While FPs confer a survival benefit for CRC patients, serious systemic toxicities, including neutropenia, occur in ~30% of patients with lethality in 0.5−1% of patients. While serious systemic toxicities may occur in any patient, patients with polymorphisms in DPYD , which encodes the rate-limiting enzyme for pyrimidine degradation are at very high risk. Other genetic factors affecting risk for 5-FU toxicity, including miR-27a, are under investigation. Methods: Literature used to inform the text of this article was selected from PubMed.gov from the National Library of Medicine while regulatory documents were identified via Google search. Conclusions: Clinical studies to date have validated four DPYD polymorphisms ( DPYD *2A, DPYD *13, c.2846A>T, HapB3) associated with serious toxicities in patients treated with 5-FU. Genetic screening for these is being implemented in the Netherlands and the UK and has been shown to be a cost-effective way to improve outcomes. Factors other than DPYD polymorphisms (e.g., miR-27a, TYMS , ENOSF1, p53) also affect 5-FU toxicity. Functional testing for deficient pyrimidine catabolism {defined as [U] >16 ng/mL or [UH2]:[U] <10} is being implemented in France and has demonstrated utility in identifying patients with elevated risk for 5-FU toxicity. Therapeutic drug monitoring (TDM) from plasma levels of 5-FU during first cycle treatment also is being used to improve outcomes and pharmacokinetic-based dosing is being used to increase the percent of patients within optimal area under the curve (AUC) (18–28 mg*h/L) values. Patients maintained in the optimal AUC range experienced significantly reduced systemic toxicities. As understanding the genetic basis for increased risk of 5-FU toxicity becomes more refined, the development of functional-based methods to optimize treatment is likely to become more widespread.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adjuvant chemotherapy is administered to reduce the risk for disease recurrence in CRC patients undergoing surgical resection for primary colon cancer with curative intent [131].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“While the anti-cancer activities of FPs result primarily from conversion to FdUMP and inhibition of TS (2,37), up to 90% of 5-FU is degraded (38).”
BackgroundFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · cited 2×
“However, its use was associated with higher incidence of toxic effects (23), demonstrating the need to better understand and manage toxicities related to FP use.”
BackgroundSargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 4×
“The mechanistic basis for lack of efficacy of FPs in dMMR CRC is not clearly understood, however MSI is also associated with elevated thymidylate synthase (TS) (20,21), which is the molecular target of FP chemotherapy (2).”
BackgroundInfluentialGill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021 · cited 1×
“An intergroup analysis reported a statistically significant improvement in 5-year DFS for stage II patients treated with chemotherapy, but improvement in overall survival was not statically significant (12).”
BackgroundAmstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694 · cited 1×
“Although >160 SNPs in DPYD have been reported (49) as outlined by the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines (6), relatively few are both highly prevalent and have a substantial effect on DPD activity to justify pre-emptive screening.”
BackgroundSargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5362 · Cited by 666 · cited 1×
“Follow-up analysis of long-term outcomes demonstrated 5-FU chemotherapy was associated with a 5% absolute improvement in survival at 8 years (13).”
Background(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30686-7 · Cited by 444 · cited 3×
“The recommendations adopted in the UK parallel results from clinical studies in the Netherlands (58) and other countries that demonstrated prospective screening for clinically-relevant DPYD variants was feasible, and that DPYD genotype to guide dose improved outcomes.”
ResultInfluential5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433 · cited 1×
“Cardiotoxicity, while relatively rare, is a potentially lethal occurrence with high risk for long-term morbidity and mortality (28), and its risk with 5-FU is second only to anthracyclines (29).”
BackgroundMicrosatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418 · cited 2×
“Gatalica Z, Vranic S, Xiu J, et al. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.”
Background
Cited by
Gmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 125
Self-citationRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Adjuvant chemotherapy is administered to reduce the risk for disease recurrence in CRC patients undergoing surgical resection for primary colon cancer with curative intent [131].”
BackgroundSelf-citationResponse to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
Hertz, D. L., Smith, D. M., Scott, S. A., Patel, J. N., & Hicks, J. K. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2978 · Cited by 35
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Ho, T. T., Smith, D. M., Aquilante, C. L., Cicali, E. J., Rouby, N. M. E., Hertz, D. L., Imanirad, I., Patel, J. N., Scott, S. A., Swain, S. M., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3567 · Cited by 33
Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity
Trepka, K. R., Kidder, W. A., Kyaw, T. S., Halsey, T. M., Olson, C. A., Ortega, E. F., Noecker, C. A., Upadhyay, V., Stanfield, D., Steiding, P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq8870 · Cited by 30
Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
Hishinuma, E., Narita, Y., Obuchi, K., Ueda, A., Saito, S., Tadaka, S., Kinoshita, K., Maekawa, M., Mano, N., Hirasawa, N., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930470 · Cited by 29
“Dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2) is a ratelimiting enzyme involved in the degradation of the endogenous nucleobases uracil and thymine, and the anticancer drug 5-fluorouracil (5-FU) (Kikugawa et al., 1994; Gmeiner, 2021).”
BackgroundInfluentialHuang, J. H., Wu, Z., & Xu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.881910 · Cited by 25
“William (2021) (19) found that 5-FU was beneficial to improve the survival rate of colorectal cancer patients, but severe systemic”
BackgroundLuca, O. D., Salerno, G., Bernardini, D. D., Torre, M. S., Simmaco, M., Lionetto, L., Gentile, G., & Borro, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213923 · Cited by 23
Okechukwu, C. C., Ma, X., Sah, N., Mani, C., Palle, K., & Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16071360 · Cited by 21
“Our results support the further development of CF10 for improved CRLM treatment that may contribute to improved outcomes for this highly lethal malignancy.”
BackgroundResultSelf-citation5-Fluorouracil (5-FU)-induced organ toxicities: mechanisms, management, and prevention strategies
Moghadamnia, A., Karim, B., Ebrahimi, P., Rahimzadeh, M. R., Nazari, Z., & Kazemi, S. (2025) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2559286 · Cited by 18
“Patients with deficits in 5-FU metabolism are more likely to have severe side effects after 5-FU treat-ment (Gmeiner 2021).”
Farinango, C., Gallardo, J., Freire‐Paspuel, B., Flores‐Espinoza, R., Jaramillo-Koupermann, G., López‐Cortés, A., Burgos, G., Tejera, E., & Cabrera‐Andrade, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060950 · Cited by 15
Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
Miarons, M., Gordón, A. M., Riera, P., Nicolás, F. G., Martín, L. A., Agustín, M. J., López, M. A. A., Castañé, M. D. A., Martín, T. Á., Beloqui, J. J., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad077 · Cited by 15
“1% (12) of the patients, the variants were found in homozygosis; specifically, the c.”
BackgroundReview of the fluoropyrimidine antidote uridine triacetate
Thompson, J., Wood, D. M., & Dargan, P. I. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16319 · Cited by 10
“26,96,114 – 118 Thus, although a developing field, pharmacogenomic screening will not obviate the need for uridine triacetate in treating severe toxicity arising through routine oncological care in the foreseeable future.”
Rouby, N. M. E., Aquilante, C. L., Bargal, S. A., Cavallari, L. H., Duarte, J. D., Gunderson, K., Mazhindu, T., Nagy, M., Nie, X., Nguyen, D. G., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70466 · Cited by 8
“Fluoropyrimidines, which include intravenous 5-fluorouracil (5-FU) and its oral prodrugs capecitabine and tegafur, are a vital component of chemotherapy regimens to treat various cancer types, with an estimated 2 million patients worldwide receiving a fluoropyrimidine each year [1, 2].”
Crystal Structure of DNA Replication Protein SsbA Complexed with the Anticancer Drug 5-Fluorouracil
Su, H.-H., Huang, Y., Lien, Y., Yang, P.-C., & Huang, C.-Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914899 · Cited by 5
“Consequently, a comprehensive elucidation of the complete 5-FU interactome is imperative, serving as the foundation for exhaustive clinical pharmacokinetic assessments and toxicity analyses [21,22].”
Montella, A., Cantalupo, S., D’Alterio, G., Damiano, V., Iolascon, A., & Capasso, M. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00223 · Cited by 4
Targeting SLC4A4: A Novel Approach in Colorectal Cancer Drug Repurposing
Pawar, K., Gupta, P. P., Solanki, P. S., Niraj, R. R. K., & Kothari, S. L. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47010067 · Cited by 3
Current Chemotherapy Strategies for Colorectal Cancer: Challenges and Future Directions
Yang, Z., Deng, X., Yang, Z., Han, M., Zanna, M. Y., Ismail, N., Razis, A. F. A., Esa, N. M., Bakar, M. Z. A., & Chan, K. W. (2025) · Asian Journal of Medicine and Biomedicine · doi:10.37231/ajmb.2025.9.1.811 · Cited by 3
“However, its use is associated with a range of side effects (shown in Table 1), the severity of which can vary depending on dosage, route of administration, and individual patient factors 99,100 .”
Ikonnikova, A. Y., Fedorinov, D. S., Gryadunov, D. A., Heydarov, R. N., Lyadova, M. A., Москаленко, А. Н., Mikhailovich, V. M., Emelyanova, M., & Lyadov, V. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158503 · Cited by 3
“Despite their proven efficiency, the use of FPs commonly leads to severe toxicity, followed by interruptions and delays in chemotherapy delivery, life-threatening events and even death [1].”
BackgroundChalloob, M. A., & Mohammed, N. S. (2023) · Cureus · doi:10.7759/cureus.44534 · Cited by 2
YÜKSEL, T., & CİNDOĞLU, Ç. (2024) · Forbes Journal of Medicine · doi:10.4274/forbes.galenos.2024.74755
Navigating Cardiotoxicity in Cancer Treatment: Insights into Fluoropyrimidine-induced Cardiac Events
Bhattarai, A., Chakraborty, M., Ali, M. K., Sharma, C., Rai, A., Acharya, R., Rai, Y., Bhattacharjee, A., & Bhuyan, N. R. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x335593250413154832
“Importantly, screening for DPD deficiency before treatment, through the identification of common DPYD polymorphisms, plays a crucial role in improving outcomes, especially when combined with personalized dose adjustments [93].”
Epigenetics in India: the uncharted frontier in personalized medicine
Samuel, S. S., Jospeh, S., Maria, S. A., & Santhosh, J. K. (2025) · Epigenetics Reports · doi:10.1080/28361512.2025.2583981
Identification of genetic factors predisposing to chemotherapy and immunotherapy toxicity
Chin, I. S. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham)
Xia, X., Hu, L., Tao, S., Li, J., & Huang, X. (2026) · Toxicological Research · doi:10.1007/s43188-025-00334-8
Pjevac, M., Bon, J., & Dolžan, V. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1828563
“…modest, phenotypes are polygenic and clinically heterogeneous (Schizophrenia Working (Maslarinou et al., 2023; Koutsilieri and Patrinos, 2020; Gmeiner, 2021); POPular Genetics: HR 0.78 (95% CI, 0.61–0.98) for PLATO major/minor bleeding (Claassens et al., 2019); thiopurine dosing: > 90%…”
InfluentialNorris, M. L., Nguyen, K. A., Cicali, E. J., Moyeno, W. M., Hong, J.-W. J., Anderson, K. V., Jang, T., Gim, G., Sullivan, K., Kennan, A., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1944703
Metadata
- Authors
- Gmeiner, W. H.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Gmeiner, William H.
- ORCID
- Gmeiner, William H.
- Venue
- Precision Cancer Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-12
- Volume
- 4
- Pages
- 38-38
- ISSN
- 2617-2216 (ISSN-L)
- PMC
- PMC8664072
- OpenAlex
- W3190206309
- Cited by
- 25
- References
- 81
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 4
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Precision Cancer Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Funders
- National Cancer Institute (R21CA218933, P30CA012197)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fluoropyrimidine toxicity, 5-fluorouracil, DPYD polymorphisms, pharmacogenomics, personalized treatment, neutropenia, colorectal cancer, genetic screening, miR-27a, pyrimidine catabolism, therapeutic drug monitoring, pharmacokinetic dosing, area under the curve, thymidylate synthase, p53, gastrointestinal toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.